Sempra (SRE) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jan, 2026Executive summary
Q1 2025 adjusted EPS was $1.44 (up from $1.34), and GAAP EPS was $1.39 (up from $1.26); net income reached $919M, up from $881M.
Strong financial performance driven by higher authorized revenues, tax benefits, and disciplined growth strategy.
Five value creation initiatives underway, including $13B capital investment, LNG franchise value unlock, non-core asset sales, cost/productivity program, and operational excellence.
Business model simplification and divestitures aim to support utility growth, strengthen the balance sheet, and enhance shareholder value.
Sempra Infrastructure and California utilities saw significant earnings increases, while Texas segment earnings declined due to higher expenses.
Financial highlights
Q1 2025 revenues were $3.8B, up from $3.6B; net income attributable to common shares was $906M, up from $801M.
Adjusted Q1 2025 earnings were $942M, up from $854M; operating income for SDG&E and SoCalGas increased year-over-year.
Sempra’s effective tax rate dropped to 7% from 21% year-over-year.
Capital expenditures for PP&E and investments totaled $2.8B in Q1 2025, up from $2.1B.
Operating cash flow was $1.5B, down from $1.9B year-over-year, mainly due to regulatory and working capital changes.
Outlook and guidance
2025 adjusted EPS guidance affirmed at $4.30–$4.70; 2026 guidance at $4.80–$5.30; long-term EPS CAGR projected at 7%–9% for 2025–2029.
2025 capital expenditures expected to total $12.5B, focusing on regulated utility and LNG infrastructure growth.
Oncor's five-year capital plan exceeds $12B, supporting rate base and earnings growth.
Asset sales of Ecogas and a minority interest in SI Partners are underway, expected to close within 12–18 months and be accretive.
Guidance does not include impacts from proposed asset sales.
Latest events from Sempra
- $65B capital plan and record adjusted EPS drive sector-leading growth outlook.SRE
Q4 202526 Feb 2026 - Q2 2024 earnings rose to $713M, with strong Texas/California growth and major projects advancing.SRE
Q2 20242 Feb 2026 - Q3 EPS fell, but guidance and $3B equity plan reaffirmed; Texas and LNG drive growth.SRE
Q3 202416 Jan 2026 - 2024 adjusted EPS hit $4.65, with a $56B capital plan and 7–9% EPS growth targeted.SRE
Q4 20247 Jan 2026 - Board refreshment, performance-based pay, and ambitious ESG targets headline the 2025 proxy.SRE
Proxy Filing1 Dec 2025 - Director nominee Jennifer M. Kirk will become CEO of Exubrion Therapeutics in May 2025.SRE
Proxy Filing1 Dec 2025 - Virtual meeting to elect 11 directors, ratify auditor, and approve executive pay.SRE
Proxy Filing1 Dec 2025 - Q2 2025 adjusted EPS held steady as utility growth, LNG progress, and guidance advanced.SRE
Q2 202523 Nov 2025 - Adjusted EPS up, major asset sale and Texas/LNG growth drive strong long-term outlook.SRE
Q3 20255 Nov 2025